Physician profile
Stephen C Williams
NPI 1184778284
$606.30
in general payments reported to CMS, 2019-2025
12 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $147 · 2022: $78.98 · 2023: $268 · 2024: $112.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $381.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $380.53 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| E.R. Squibb & Sons, L.L.C. | $112.42 | 2024 | Cobenfy |
| Abbvie INC. | $106.79 | 2023 | Vraylar |
| Indivior INC. | $69.28 | 2019 | |
| Otsuka America Pharmaceutical, INC. | $65.91 | 2019-2023 | Abilify Maintena, Rexulti |
| Alkermes, INC. | $59.36 | 2019-2023 | Aristada, Lybalvi |
| Janssen Pharmaceuticals, INC | $44.71 | 2019-2023 | Invega Sustenna |
| Takeda Pharmaceuticals U.S.A., INC. | $35.08 | 2022-2023 | Trintellix |
| Neurocrine Biosciences, INC. | $32.49 | 2023 | Ingrezza |
| Teva Pharmaceuticals USA, INC. | $30.68 | 2022-2023 | Austedo |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $18.43 | 2023 | |
| Axsome Therapeutics, INC. | $16.98 | 2023 | Auvelity |
| Cumberland Pharmaceuticals, INC. | $14.17 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Stephen Williams listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.